|
US8586781B2
(en)
|
1998-04-02 |
2013-11-19 |
Mbc Pharma, Inc. |
Bone targeted therapeutics and methods of making and using the same
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
EP2660322A3
(en)
*
|
2003-04-17 |
2013-11-13 |
Alnylam Pharmaceuticals Inc. |
Modified iRNA agents
|
|
US8575327B2
(en)
|
2003-06-12 |
2013-11-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
|
EP2231194B1
(en)
*
|
2007-12-04 |
2017-02-22 |
Alnylam Pharmaceuticals Inc. |
Folate-irna conjugates
|
|
JP5635412B2
(ja)
*
|
2007-12-04 |
2014-12-03 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
標的化脂質
|
|
EP2274425A2
(en)
*
|
2008-04-11 |
2011-01-19 |
Alnylam Pharmaceuticals Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CN102405286A
(zh)
|
2008-09-22 |
2012-04-04 |
阿克赛医药公司 |
减小大小的自递送RNAi化合物
|
|
EP2379084B1
(en)
|
2008-10-15 |
2017-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
CA3222620A1
(en)
|
2008-10-20 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
CN111909020A
(zh)
*
|
2008-11-10 |
2020-11-10 |
阿布特斯生物制药公司 |
用于递送治疗剂的脂质和组合物
|
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
US20120101148A1
(en)
*
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
CA2753975C
(en)
|
2009-03-02 |
2017-09-26 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
|
CA2764158A1
(en)
|
2009-06-01 |
2010-12-09 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent rna interference, compositions and methods of use thereof
|
|
CN102458366B
(zh)
*
|
2009-06-15 |
2015-02-11 |
阿尔尼拉姆医药品有限公司 |
靶向pcsk9基因的脂质配制的dsrna
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
ES2666559T3
(es)
|
2009-12-01 |
2018-05-07 |
Translate Bio, Inc. |
Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
|
|
WO2011102904A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Robert Shorr |
Imageable lipid-oil-water nanoemulsion therapeutic delivery system
|
|
WO2011102905A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Robert Shorr |
Imageable lipid-oil-water nanoemulsion diagnostic delivery system
|
|
WO2011102906A1
(en)
*
|
2010-02-19 |
2011-08-25 |
Robert Shorr |
Imageable lipid-oil-water nanoemulsion delivery system
|
|
KR20180044433A
(ko)
|
2010-03-24 |
2018-05-02 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
|
|
RU2615143C2
(ru)
*
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
|
US8507663B2
(en)
|
2010-04-06 |
2013-08-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
|
|
US9145556B2
(en)
|
2010-04-13 |
2015-09-29 |
Life Technologies Corporation |
Compositions and methods for inhibition of nucleic acids function
|
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
|
US20130071321A1
(en)
|
2010-05-28 |
2013-03-21 |
Purdue Research Foundation |
Delivery of agents to inflamed tissues using folate-targeted liposomes
|
|
US8785121B2
(en)
|
2010-07-08 |
2014-07-22 |
Bonac Corporation |
Single-stranded nucleic acid molecule for controlling gene expression
|
|
CA2805739A1
(en)
*
|
2010-07-28 |
2012-02-02 |
Smartcells, Inc. |
Drug-ligand conjugates, synthesis thereof, and intermediates thereto
|
|
US8691782B2
(en)
|
2010-08-03 |
2014-04-08 |
Bonac Corporation |
Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
|
|
CN103052711B
(zh)
*
|
2010-08-03 |
2016-08-03 |
株式会社博纳克 |
具有含氮脂环式骨架的单链核酸分子
|
|
KR20130137160A
(ko)
|
2010-08-24 |
2013-12-16 |
머크 샤프 앤드 돔 코포레이션 |
내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제
|
|
AU2011302152B2
(en)
*
|
2010-09-15 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
CN101974152B
(zh)
*
|
2010-09-28 |
2012-07-11 |
山东大学 |
一种类脂-阳离子聚合物及其制备方法
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
CA2817960C
(en)
|
2010-11-17 |
2020-06-09 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
MX346144B
(es)
|
2010-12-17 |
2017-03-09 |
Arrowhead Res Corp * |
Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.
|
|
CA2976966C
(en)
|
2010-12-29 |
2021-11-09 |
F. Hoffmann-La Roche Ag |
Small molecule conjugates for intracellular delivery of nucleic acids
|
|
EP3202760B1
(en)
|
2011-01-11 |
2019-08-21 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
CN103813810B
(zh)
*
|
2011-03-29 |
2021-08-03 |
阿尔尼拉姆医药品有限公司 |
用于抑制tmprss6基因表达的组合物和方法
|
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
CN120555426A
(zh)
|
2011-06-21 |
2025-08-29 |
阿尔尼拉姆医药品有限公司 |
血管生成素样3（ANGPTL3）iRNA组合物及其使用方法
|
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
|
WO2012177921A2
(en)
*
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
|
|
KR102540778B1
(ko)
|
2011-06-21 |
2023-06-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
KR102167524B1
(ko)
|
2011-06-30 |
2020-10-20 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
|
|
US9334300B2
(en)
|
2011-08-01 |
2016-05-10 |
Mbc Pharma, Inc. |
Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換ｐｅｇ化脂質
|
|
EP2594575A1
(en)
*
|
2011-11-15 |
2013-05-22 |
Université de Strasbourg |
Mannosylated compounds useful for the prevention and the treatment of infectious diseases
|
|
LT3366775T
(lt)
|
2011-11-18 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Modifikuoti rnri agentai
|
|
RU2678807C2
(ru)
*
|
2011-11-18 |
2019-02-01 |
Элнилэм Фармасьютикалз, Инк. |
СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
|
|
ES2921724T1
(es)
|
2011-12-07 |
2022-08-31 |
Alnylam Pharmaceuticals Inc |
Lípidos biodegradables para la administración de agentes activos
|
|
MX357392B
(es)
|
2012-04-02 |
2018-07-06 |
Berg Llc |
Ensayos basados en interrogatorios celulares y uso de los mismos.
|
|
US9133461B2
(en)
*
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
*
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
TWI595885B
(zh)
*
|
2012-05-02 |
2017-08-21 |
喜納製藥公司 |
包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
US9663784B2
(en)
*
|
2012-05-26 |
2017-05-30 |
Bonac Corporation |
Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
|
|
KR20200118233A
(ko)
|
2012-06-01 |
2020-10-14 |
버그 엘엘씨 |
조효소 q10을 이용한 고형 종양의 치료
|
|
WO2013183656A1
(ja)
*
|
2012-06-04 |
2013-12-12 |
大日本住友製薬株式会社 |
Ｇタンパク質共役受容体結合リガンドと核酸分子とのコンジュゲート
|
|
EP2859102A4
(en)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
|
|
CA2876155C
(en)
|
2012-06-08 |
2022-12-13 |
Ethris Gmbh |
Pulmonary delivery of mrna to non-lung target cells
|
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
癌を処置するための組成物および該組成物を製造するための方法
|
|
EP4253395A3
(en)
*
|
2012-08-06 |
2023-11-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for the preparation of carbohydrate conjugated rna agents
|
|
CN102824515B
(zh)
*
|
2012-09-18 |
2015-05-20 |
淄博齐鼎立专利信息咨询有限公司 |
热毒清片在制备抑制a-204细胞增殖药物中的应用
|
|
JP2016503394A
(ja)
|
2012-10-26 |
2016-02-04 |
エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． |
細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法
|
|
CN117126846A
(zh)
|
2012-11-15 |
2023-11-28 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸缀合物
|
|
US9506897B2
(en)
|
2012-11-16 |
2016-11-29 |
Agilent Technologies, Inc. |
Methods and compositions for improved ion-exchange chromatography
|
|
SMT201800039T1
(it)
*
|
2012-12-05 |
2018-03-08 |
Alnylam Pharmaceuticals Inc |
Composizioni di irna di pcsk9 e metodi di uso delle stesse
|
|
US20150337318A1
(en)
*
|
2013-01-11 |
2015-11-26 |
Phaserx Inc. |
Rna targeted to c-met
|
|
CA2893801A1
(en)
*
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
|
CN120574828A
(zh)
*
|
2013-03-14 |
2025-09-02 |
阿尔尼拉姆医药品有限公司 |
补体组分C5 iRNA组合物及其使用方法
|
|
EP4446413A3
(en)
|
2013-03-14 |
2024-12-18 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
HUE055044T2
(hu)
|
2013-03-14 |
2021-10-28 |
Translate Bio Inc |
MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények
|
|
WO2014153052A2
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Cftr mrna compositions and related methods and uses
|
|
KR20150131365A
(ko)
|
2013-03-15 |
2015-11-24 |
미라젠 세러퓨틱스 인코포레이티드 |
브리지드 바이사이클릭 뉴클레오시드
|
|
ES2795249T3
(es)
|
2013-03-15 |
2020-11-23 |
Translate Bio Inc |
Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas
|
|
MX380565B
(es)
|
2013-04-08 |
2025-03-12 |
Berg Llc |
Terapias combinadas de coenzima q10 para el tratamiento de cáncer.
|
|
TWI680767B
(zh)
|
2013-05-01 |
2020-01-01 |
美商雷格勒斯治療公司 |
用於增強的細胞攝取之化合物及方法
|
|
SG11201508925WA
(en)
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
AR096203A1
(es)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
|
|
RU2535052C1
(ru)
*
|
2013-05-21 |
2014-12-10 |
Владимир Николаевич Иванов |
Фармацевтическая композиция, содержащая производные лизина, пролина и тритерпеновой кислоты для лечения и профилактики вирусных инфекций, вызываемых рнк и днк-содержащими вирусами, такими как: грипп, герпес, опоясывающий лишай, папиллома человека, аденоновирусы, а также бактериальных инфекций, вызываемых грам-положительными и грам-отрицательными микроорганизмами
|
|
PL2999785T3
(pl)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje iRNA Serpina1 i sposoby ich zastosowania
|
|
SG10202103166XA
(en)
*
|
2013-05-22 |
2021-04-29 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
|
EP3564374A1
(en)
|
2013-06-21 |
2019-11-06 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
SG11201510656PA
(en)
|
2013-06-27 |
2016-01-28 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
|
JP6422961B2
(ja)
*
|
2013-07-05 |
2018-11-14 |
バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ |
改善された高効率ナノ粒子型オリゴヌクレオチド構造体およびその製造方法
|
|
CA3177846A1
(en)
|
2013-07-11 |
2015-01-15 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide-ligand conjugates and process for their preparation
|
|
AU2014315186B2
(en)
|
2013-09-04 |
2020-02-27 |
Berg Llc |
Methods of treatment of cancer by continuous infusion of coenzyme Q10
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
TW201610151A
(zh)
|
2013-09-23 |
2016-03-16 |
阿尼拉製藥公司 |
治療或預防與甲狀腺素運載蛋白相關疾病之方法
|
|
CA2925107A1
(en)
|
2013-10-02 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EP3052628B1
(en)
*
|
2013-10-04 |
2020-02-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
|
EP4036241A1
(en)
|
2013-10-22 |
2022-08-03 |
Translate Bio, Inc. |
Cns delivery of mrna and uses thereof
|
|
CN105658242A
(zh)
|
2013-10-22 |
2016-06-08 |
夏尔人类遗传性治疗公司 |
用于苯丙酮尿症的mrna疗法
|
|
AU2014340155B2
(en)
|
2013-10-22 |
2018-11-01 |
Massachusetts Institute Of Technology |
Lipid formulations for delivery of messenger RNA
|
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
|
US20160289677A1
(en)
*
|
2013-11-14 |
2016-10-06 |
Roche Innovation Center Copenhagen A/S |
APOB Antisense Conjugate Compounds
|
|
CN113151180A
(zh)
|
2013-12-02 |
2021-07-23 |
菲奥医药公司 |
癌症的免疫治疗
|
|
SG11201604692UA
(en)
|
2013-12-12 |
2016-07-28 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
JP6486836B2
(ja)
|
2013-12-26 |
2019-03-20 |
学校法人東京医科大学 |
遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
|
|
KR102357337B1
(ko)
|
2013-12-27 |
2022-01-28 |
가부시키가이샤 보낙 |
유전자 발현 제어를 위한 인공 매치형 miRNA 및 그 용도
|
|
WO2015106128A2
(en)
*
|
2014-01-09 |
2015-07-16 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED RNAi AGENTS
|
|
WO2015107115A1
(en)
*
|
2014-01-15 |
2015-07-23 |
Basf Se |
Saccharide-modified nucleic acid molecules
|
|
WO2015113922A1
(en)
|
2014-01-30 |
2015-08-06 |
Roche Innovation Center Copenhagen A/S |
Poly oligomer compound with biocleavable conjugates
|
|
CN106103718B
(zh)
|
2014-02-11 |
2021-04-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
|
RU2019130898A
(ru)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
Композиции для модуляции экспрессии атаксина 2
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
SG10201910844SA
(en)
|
2014-04-01 |
2020-01-30 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
US10426753B2
(en)
|
2014-04-03 |
2019-10-01 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
|
CN106164248B
(zh)
|
2014-04-25 |
2019-10-15 |
川斯勒佰尔公司 |
信使rna的纯化方法
|
|
WO2015168108A2
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic targeting mdm2 or mycn
|
|
EP3137476B1
(en)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
EP3137115B1
(en)
*
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
WO2015168532A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating pkk expression
|
|
KR20200102553A
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
|
DK3137596T3
(da)
|
2014-05-01 |
2019-09-02 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression
|
|
AU2015252895B2
(en)
|
2014-05-01 |
2021-07-15 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
|
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
WO2015179724A1
(en)
|
2014-05-22 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
CN106659731A
(zh)
|
2014-05-30 |
2017-05-10 |
夏尔人类遗传性治疗公司 |
用于递送核酸的可生物降解脂质
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
JP6599373B2
(ja)
|
2014-06-24 |
2019-10-30 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
核酸の送達のための立体化学的に濃縮した組成物
|
|
EP3160938B1
(en)
|
2014-06-25 |
2020-09-16 |
Acuitas Therapeutics Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US9668980B2
(en)
|
2014-07-02 |
2017-06-06 |
Rana Therapeutics, Inc. |
Encapsulation of messenger RNA
|
|
BR112017001931A2
(pt)
|
2014-08-07 |
2017-11-28 |
Regulus Therapeutics Inc |
direcionamento de micrornas para distúrbios metabólicos
|
|
WO2016030863A1
(en)
|
2014-08-29 |
2016-03-03 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds and methods for treating viral infections
|
|
US10060921B2
(en)
|
2014-08-29 |
2018-08-28 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (TTR) mediated amyloidosis
|
|
KR102689262B1
(ko)
|
2014-09-05 |
2024-07-30 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
SG11201702682PA
(en)
|
2014-10-03 |
2017-04-27 |
Cold Spring Harbor Lab |
Targeted augmentation of nuclear gene output
|
|
WO2016057693A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
CA2961993A1
(en)
|
2014-10-10 |
2016-04-14 |
F. Hoffmann-La Roche Ag |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
US11203776B2
(en)
|
2014-11-12 |
2021-12-21 |
Tumorend, Llc |
Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration
|
|
US10822369B2
(en)
|
2014-11-14 |
2020-11-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
|
|
WO2016085852A1
(en)
|
2014-11-24 |
2016-06-02 |
Alnylam Pharmaceuticals, Inc. |
Tmprss6 irna compositions and methods of use thereof
|
|
EP3226912B1
(en)
|
2014-12-05 |
2021-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of articular disease
|
|
WO2016094425A1
(en)
|
2014-12-08 |
2016-06-16 |
Berg Llc |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
|
US12359197B2
(en)
|
2014-12-12 |
2025-07-15 |
Etagen Pharma, Inc. |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
|
DK3569711T3
(da)
*
|
2014-12-15 |
2021-02-22 |
Dicerna Pharmaceuticals Inc |
Ligandmodificerede dobbeltstrengede nukleinsyrer
|
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
|
CA2972065A1
(en)
*
|
2014-12-23 |
2016-06-30 |
Intellectual Property Associates, Llc |
Methods and formulations for transdermal administration
|
|
MX381947B
(es)
|
2014-12-27 |
2025-03-11 |
Bonac Corp |
Mirna natural para controlar la expresion de gen y uso del mismo.
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
US20180002692A1
(en)
*
|
2015-01-30 |
2018-01-04 |
Anushree Chatterjee |
Sequence Specific and Organism Specific Antimicrobials and Related Materials and Methods
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
CN104804463B
(zh)
*
|
2015-03-10 |
2016-08-24 |
西安交通大学第一附属医院 |
用于靶向肿瘤组织的近红外荧光染色剂及制备方法和应用
|
|
JP6895892B2
(ja)
|
2015-03-19 |
2021-06-30 |
トランスレイト バイオ， インコーポレイテッド |
ポンペ病のｍＲＮＡ治療
|
|
JP6602847B2
(ja)
|
2015-03-27 |
2019-11-06 |
株式会社ボナック |
デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
|
|
CN107429250B
(zh)
|
2015-04-03 |
2022-03-01 |
Ionis制药公司 |
用于调节tmprss6表达的化合物和方法
|
|
EP3277811B1
(en)
|
2015-04-03 |
2020-12-23 |
University of Massachusetts |
Fully stabilized asymmetric sirna
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
KR20250005546A
(ko)
|
2015-04-13 |
2025-01-09 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법
|
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US10709728B2
(en)
|
2015-06-01 |
2020-07-14 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof
|
|
CN104987360A
(zh)
*
|
2015-06-04 |
2015-10-21 |
大连民族学院 |
一类双烷氧酰胺烷基阳离子肽脂质及其合成方法和应用
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
AU2016285852B2
(en)
|
2015-06-29 |
2020-12-17 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
GB201511459D0
(en)
*
|
2015-06-30 |
2015-08-12 |
Cell Therapy Ltd |
Sirna microbubble
|
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
CN108135923B
(zh)
|
2015-07-06 |
2021-03-02 |
菲奥医药公司 |
靶向超氧化物歧化酶1（sod1）的核酸分子
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
AU2016294347B2
(en)
|
2015-07-10 |
2022-07-28 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
|
|
EP3324980B1
(en)
|
2015-07-17 |
2021-11-10 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
|
WO2017019660A1
(en)
|
2015-07-27 |
2017-02-02 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
|
JP6896703B2
(ja)
|
2015-07-31 |
2021-06-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
|
|
NZ739902A
(en)
|
2015-07-31 |
2022-09-30 |
Arcturus Therapeutics Inc |
Multiligand agent for drug delivery
|
|
AU2016306275A1
(en)
|
2015-08-07 |
2018-02-08 |
Arrowhead Pharmaceuticals, Inc. |
RNAi therapy for Hepatitis B virus infection
|
|
US10633653B2
(en)
|
2015-08-14 |
2020-04-28 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
AU2016310494B2
(en)
|
2015-08-25 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
|
|
AU2016315584B2
(en)
|
2015-09-02 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
|
|
RU2018113709A
(ru)
|
2015-09-24 |
2019-10-30 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии kras
|
|
PT3353303T
(pt)
|
2015-09-25 |
2023-10-10 |
Academisch Ziekenhuis Leiden |
Composições e métodos para modulação da expressão de ataxina 3
|
|
JP2018530325A
(ja)
|
2015-10-08 |
2018-10-18 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
アンジオテンシノーゲンの発現を調節するための化合物及び方法
|
|
JP2018535197A
(ja)
*
|
2015-10-09 |
2018-11-29 |
ダイス モレキュルズ エスヴィー， エルエルシーＤｉｃｅ Ｍｏｌｅｃｕｌｅｓ Ｓｖ， Ｌｌｃ |
タグ付きコンビナトリアルライブラリ化合物のＬｏｇＤを推定する方法
|
|
US10196639B2
(en)
|
2015-10-09 |
2019-02-05 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
WO2017066573A1
(en)
|
2015-10-14 |
2017-04-20 |
Shire Human Genetic Therapies, Inc. |
Modification of rna-related enzymes for enhanced production
|
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SMALL SELF-LEANING NUCLEIC ACID COMPOUNDS TURNED AGAINST LONG NON-CODING RNA
|
|
FI3368507T3
(fi)
|
2015-10-28 |
2023-03-21 |
Acuitas Therapeutics Inc |
Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi
|
|
DK4119569T3
(da)
|
2015-11-06 |
2024-08-12 |
Ionis Pharmaceuticals Inc |
Konjugerede antisense-forbindelser til anvendelse i behandling
|
|
CA2999341A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
TWI836281B
(zh)
|
2015-12-07 |
2024-03-21 |
美商健贊公司 |
治療ｓｅｒｐｉｎｃ１相關疾患之方法及組成物
|
|
WO2017100587A1
(en)
*
|
2015-12-09 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
|
|
JP7049248B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
常染色体優性精神遅滞－５とドラベ症候群の処置のためのアンチセンスオリゴマー
|
|
EP3389671A4
(en)
|
2015-12-14 |
2019-07-17 |
Cold Spring Harbor Laboratory |
ANTISENSE OLIGOMERS FOR THE TREATMENT OF ALAGILLE SYNDROME
|
|
CA3005254A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
|
|
EP4104867A3
(en)
|
2015-12-14 |
2023-03-01 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of central nervous system diseases
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
EP3389672A4
(en)
|
2015-12-14 |
2019-08-14 |
Cold Spring Harbor Laboratory |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF LIVER DISEASES
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
CA3006015A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
|
ES2858090T3
(es)
|
2016-01-29 |
2021-09-29 |
Kyowa Kirin Co Ltd |
Complejo de ácidos nucleicos
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
MX2018010633A
(es)
|
2016-03-03 |
2019-06-13 |
Univ Massachusetts |
Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
|
|
CA3011946A1
(en)
*
|
2016-03-07 |
2017-09-14 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
EP3436066A1
(en)
|
2016-04-01 |
2019-02-06 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
CA3020343A1
(en)
|
2016-04-08 |
2017-10-12 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
MA45478A
(fr)
*
|
2016-04-11 |
2019-02-20 |
Arbutus Biopharma Corp |
Compositions de conjugués d'acides nucléiques ciblés
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
WO2017184786A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Cpf1 complexes with reduced indel activity
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
MA45295A
(fr)
*
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
SG11201809002RA
(en)
|
2016-04-29 |
2018-11-29 |
Univ Nanyang Tech |
G-quadruplex-containing antisense oligonucleotides
|
|
US11040108B2
(en)
|
2016-04-29 |
2021-06-22 |
Brandeis University |
Amino acid- and peptide-steroid conjugates and use thereof
|
|
EP3452055A4
(en)
|
2016-05-06 |
2019-11-06 |
Tod M. Woolf |
IMPROVED METHODS FOR GENERIC MODIFICATION WITH AND WITHOUT PROGRAMMABLE NUCLEASES
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
US10835583B2
(en)
|
2016-06-13 |
2020-11-17 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
JP7022687B2
(ja)
*
|
2016-06-30 |
2022-02-18 |
協和キリン株式会社 |
核酸複合体
|
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
|
AU2017296195A1
(en)
|
2016-07-11 |
2019-01-24 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
US10781175B2
(en)
|
2016-07-15 |
2020-09-22 |
Am Chemicals Llc |
Solid supports and phosphoramidite building blocks for oligonucleotide conjugates
|
|
CA3030864A1
(en)
|
2016-07-15 |
2018-01-18 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
US11753638B2
(en)
|
2016-08-12 |
2023-09-12 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CA3033867A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
KR102403408B1
(ko)
|
2016-09-02 |
2022-05-30 |
애로우헤드 파마슈티컬스 인코포레이티드 |
표적화 리간드
|
|
KR101933767B1
(ko)
|
2016-09-05 |
2018-12-28 |
(의료)길의료재단 |
발기부전 환자를 위한 콘돔
|
|
WO2018067900A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
EP3554535A4
(en)
|
2016-12-14 |
2020-10-21 |
Janssen Biotech, Inc. |
PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
|
|
BR112019012154A2
(pt)
|
2016-12-14 |
2019-11-12 |
Janssen Biotech, Inc. |
domínios do tipo iii da fibronectina de ligação a cd8a
|
|
KR20190098181A
(ko)
|
2016-12-16 |
2019-08-21 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
|
JP7348064B2
(ja)
|
2017-01-09 |
2023-09-20 |
アポセンス リミテッド |
分子を経膜送達するための化合物及び方法
|
|
KR102675026B1
(ko)
|
2017-01-10 |
2024-06-17 |
애로우헤드 파마슈티컬스 인코포레이티드 |
알파-1 항트립신 (AAT) RNAi 작용제, AAT RNAi 작용제를 포함하는 조성물, 및 사용 방법
|
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
|
CN106986942B
(zh)
*
|
2017-02-28 |
2020-12-25 |
国药中生生物技术研究院有限公司 |
一种包含蝙蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
|
|
US11963974B2
(en)
|
2017-03-10 |
2024-04-23 |
National Center For Child Health And Development |
Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
EP3603648B1
(en)
*
|
2017-03-29 |
2025-09-17 |
Shionogi & Co., Ltd |
Complex of nucleic acid medicine and multibranched lipid
|
|
RS63836B1
(sr)
|
2017-04-05 |
2023-01-31 |
Silence Therapeutics Gmbh |
Proizvodi i sastavi
|
|
EP3385272A1
(en)
*
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Further novel oligonucleotide-ligand conjugates
|
|
WO2018185253A1
(en)
*
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Ligand modified double-stranded nucleic acids
|
|
KR20250145702A
(ko)
|
2017-04-11 |
2025-10-13 |
아뷰터스 바이오파마 코포레이션 |
표적화 조성물
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
WO2018195165A1
(en)
|
2017-04-18 |
2018-10-25 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
|
IL301115A
(en)
|
2017-04-28 |
2023-05-01 |
Acuitas Therapeutics Inc |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
US11273222B2
(en)
*
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
CN110799647A
(zh)
|
2017-06-23 |
2020-02-14 |
马萨诸塞大学 |
双尾自递送sirna及相关的方法
|
|
EP3645546A4
(en)
|
2017-06-30 |
2021-12-01 |
Solstice Biologics, Ltd. |
CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
|
|
US10195286B2
(en)
*
|
2017-07-04 |
2019-02-05 |
Aposense Ltd. |
Compounds and methods for trans-membrane delivery of molecules
|
|
JP2020530442A
(ja)
|
2017-07-10 |
2020-10-22 |
ジェンザイム・コーポレーション |
血友病を有する対象の出血事象を処置するための方法および組成物
|
|
US11261447B2
(en)
|
2017-07-13 |
2022-03-01 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
|
|
WO2019027999A1
(en)
*
|
2017-07-31 |
2019-02-07 |
Ohio State Innovation Foundation |
BIOMIMETIC NANOMATERIALS AND USES THEREOF
|
|
WO2019027015A1
(ja)
*
|
2017-08-02 |
2019-02-07 |
協和発酵キリン株式会社 |
核酸複合体
|
|
WO2019027009A1
(ja)
*
|
2017-08-02 |
2019-02-07 |
協和発酵キリン株式会社 |
核酸複合体
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036000A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
KR102318434B1
(ko)
|
2017-08-25 |
2021-11-01 |
스톡 테라퓨틱스, 인크. |
병태 및 질환 치료용 안티센스 올리고머
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
CA3075219A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
|
EP3679140B1
(en)
*
|
2017-09-08 |
2022-11-16 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
WO2019051642A1
(zh)
*
|
2017-09-12 |
2019-03-21 |
广州中科蓝华生物科技有限公司 |
一种转染细胞内寄生虫的试剂盒及其应用
|
|
US10995335B2
(en)
|
2017-09-14 |
2021-05-04 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
|
|
WO2019053661A2
(en)
*
|
2017-09-14 |
2019-03-21 |
Alios Biopharma, Inc. |
GALNAC DERIVATIVES
|
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
|
EP3700570B1
(en)
|
2017-10-23 |
2025-01-08 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
|
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
CA3081910A1
(en)
|
2017-11-13 |
2019-05-16 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
WO2019105419A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
EP3719125B1
(en)
|
2017-12-01 |
2025-01-08 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing same, and preparation method and use
|
|
CA3083968C
(en)
|
2017-12-01 |
2024-04-23 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
EP3718572B1
(en)
|
2017-12-01 |
2024-07-31 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
EA202091520A1
(ru)
|
2017-12-18 |
2020-10-05 |
Элнилэм Фармасьютикалз, Инк. |
Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения
|
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
AU2018392782B2
(en)
|
2017-12-21 |
2023-08-31 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
AU2017444369B2
(en)
*
|
2017-12-26 |
2022-02-24 |
Guangzhou Ribobio Co., Ltd. |
Modified oligonucleotides and compound that can be used for synthesizing same
|
|
KR102617947B1
(ko)
|
2017-12-29 |
2023-12-27 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
접합체와 제조 및 그 용도
|
|
WO2019130319A1
(en)
|
2018-01-01 |
2019-07-04 |
Aposense Ltd. |
Compounds and methods for trans-membrane delivery of molecules
|
|
EP3737424A4
(en)
*
|
2018-01-10 |
2021-10-27 |
Translate Bio MA, Inc. |
COMPOSITIONS AND METHODS TO FACILITATE THE DELIVERY OF SYNTHETIC NUCLEIC ACIDS INTO CELLS
|
|
WO2019140452A1
(en)
|
2018-01-15 |
2019-07-18 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
CA3090901A1
(en)
|
2018-02-12 |
2019-08-15 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
SG11202007644PA
(en)
|
2018-02-14 |
2020-09-29 |
Deep Genomics Incorporated |
Oligonucleotide therapy for wilson disease
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
|
CN115976028B
(zh)
|
2018-03-09 |
2025-03-25 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
CN110305137A
(zh)
*
|
2018-03-20 |
2019-10-08 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
CN110305134B
(zh)
*
|
2018-03-20 |
2022-02-22 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
CN110305136A
(zh)
*
|
2018-03-20 |
2019-10-08 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
CN110305135B
(zh)
*
|
2018-03-20 |
2022-02-22 |
鲁南制药集团股份有限公司 |
一种培美曲塞二钠中间体及其制备方法
|
|
EP3768694A4
(en)
|
2018-03-22 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
EP3775207A1
(en)
|
2018-04-05 |
2021-02-17 |
Silence Therapeutics GmbH |
Sirnas with vinylphosphonate at the 5' end of the antisense strand
|
|
WO2019193189A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Silence Therapeutics Gmbh |
siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
|
|
EP3550021A1
(en)
*
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions for inhibiting expression of a target gene
|
|
EP3775218A1
(en)
|
2018-04-09 |
2021-02-17 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
KR20200141481A
(ko)
|
2018-04-11 |
2020-12-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ezh2 발현의 조절제
|
|
EP4242307A3
(en)
|
2018-04-12 |
2023-12-27 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US12060558B2
(en)
|
2018-05-04 |
2024-08-13 |
Stoke Therapeutics, Inc. |
Methods and compositions for treatment of cholesteryl ester storage disease
|
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
|
CA3098144A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
|
|
IL279102B2
(en)
*
|
2018-05-30 |
2024-10-01 |
Dtx Pharma Inc |
Lipid-modified nucleic acid compounds and methods
|
|
WO2019241648A1
(en)
|
2018-06-14 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing stmn2 expression
|
|
US20210251994A1
(en)
|
2018-06-15 |
2021-08-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
KR102059815B1
(ko)
|
2018-07-09 |
2019-12-27 |
삼성전기주식회사 |
안테나 기판 및 이를 포함하는 안테나 모듈
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
CN112424356A
(zh)
|
2018-07-20 |
2021-02-26 |
莱古路斯治疗法股份有限公司 |
用于经口递送寡核苷酸的方法
|
|
EP3826645A4
(en)
|
2018-07-25 |
2023-05-17 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION
|
|
US20210292768A1
(en)
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
AU2019316640A1
(en)
|
2018-08-10 |
2021-03-18 |
University Of Massachusetts |
Modified oligonucleotides targeting SNPs
|
|
CA3106701A1
(en)
|
2018-08-13 |
2020-02-20 |
Alnylam Pharmaceuticals, Inc. |
Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
|
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
|
CN111655849B
(zh)
|
2018-08-21 |
2024-05-10 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
EP3840759A4
(en)
|
2018-08-23 |
2022-06-01 |
University Of Massachusetts |
O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
|
|
KR20210060480A
(ko)
|
2018-08-24 |
2021-05-26 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 정제 방법
|
|
WO2020060986A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
TW202542311A
(zh)
|
2018-09-19 |
2025-11-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
AU2019350765A1
(en)
|
2018-09-28 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated ocular diseases
|
|
CN111655297A
(zh)
|
2018-09-30 |
2020-09-11 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
WO2020102630A1
(en)
|
2018-11-15 |
2020-05-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf5 expression
|
|
BR112021007476A2
(pt)
|
2018-11-21 |
2021-11-03 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir a expressão de príon
|
|
CA3120647A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
US12416004B2
(en)
|
2018-11-23 |
2025-09-16 |
Sanofi |
RNA compositions and methods for inhibiting ANGPTL8
|
|
CA3121449A1
(en)
|
2018-11-30 |
2020-06-04 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
JP7109674B2
(ja)
*
|
2018-11-30 |
2022-07-29 |
キロノヴァ （シアメン） バイオファーマ カンパニー リミテッド |
肝臓標的化特異的リガンドと甲状腺ホルモン受容体アゴニストとを含有する医薬品
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
CN119061010A
(zh)
|
2018-12-10 |
2024-12-03 |
美国安进公司 |
经化学修饰的RNAi构建体及其用途
|
|
CN113166761B
(zh)
|
2018-12-10 |
2025-09-09 |
美国安进公司 |
用于抑制pnpla3表达的rnai构建体
|
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ， インコーポレイテッド |
Ｋｃｎｔ１関連障害の治療のための組成物及び方法
|
|
WO2020132564A1
(en)
|
2018-12-21 |
2020-06-25 |
Ionis Pharmaceuticals, Inc. |
Modulators of hsd17b13 expression
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
CN111377985B
(zh)
*
|
2018-12-29 |
2023-11-10 |
苏州瑞博生物技术股份有限公司 |
化合物和缀合物及其制备方法和用途
|
|
CN113474328B
(zh)
|
2019-01-11 |
2025-07-11 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
|
BR112021013956A2
(pt)
|
2019-01-16 |
2021-09-21 |
Genzyme Corporation |
Composições de irna de serpinc1 e métodos de uso das mesmas
|
|
CN118562796A
(zh)
*
|
2019-01-18 |
2024-08-30 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
AU2020207935A1
(en)
|
2019-01-18 |
2021-08-26 |
University Of Massachusetts |
Dynamic pharmacokinetic-modifying anchors
|
|
EP3917540A1
(en)
|
2019-01-31 |
2021-12-08 |
Ionis Pharmaceuticals, Inc. |
Modulators of yap1 expression
|
|
CA3131700A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
|
HUE071494T2
(hu)
|
2019-03-29 |
2025-09-28 |
Ionis Pharmaceuticals Inc |
Vegyületek és eljárások az UBE3A-ATS modulálására
|
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
|
EP3969052A1
(en)
|
2019-05-17 |
2022-03-23 |
Alnylam Pharmaceuticals Inc. |
Oral delivery of oligonucleotides
|
|
US20240200060A1
(en)
|
2019-05-22 |
2024-06-20 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
EP3974530A4
(en)
|
2019-05-22 |
2023-07-12 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD FOR PREPARATION AND USE
|
|
EP3974532A4
(en)
|
2019-05-22 |
2024-01-24 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PROCESS OF PREPARATION AND USE
|
|
EP3974533A4
(en)
|
2019-05-22 |
2023-11-08 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PROCESS OF PREPARATION AND USE
|
|
US20220315929A1
(en)
|
2019-05-24 |
2022-10-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
|
|
CN118599833A
(zh)
|
2019-05-24 |
2024-09-06 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
WO2020238763A1
(zh)
|
2019-05-24 |
2020-12-03 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
BR112021024080A2
(pt)
|
2019-05-30 |
2022-02-08 |
Amgen Inc |
Construtos de rnai para inibir a expressão de scap e métodos de uso dos mesmos
|
|
EP3990465A1
(en)
|
2019-06-25 |
2022-05-04 |
Amgen Inc. |
Purification methods for carbohydrate-linked oligonucleotides
|
|
CN110218728A
(zh)
*
|
2019-06-28 |
2019-09-10 |
厦门甘宝利生物医药有限公司 |
一种新化合物及其应用
|
|
EP3956450B1
(en)
|
2019-07-26 |
2025-08-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030213A1
(en)
|
2019-08-09 |
2021-02-18 |
University Of Massachusetts |
Chemically modified oligonucleotides targeting snps
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4013871A1
(en)
|
2019-08-13 |
2022-06-22 |
Amgen Inc. |
Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
|
|
CN114585633A
(zh)
|
2019-08-19 |
2022-06-03 |
米纳治疗有限公司 |
寡核苷酸缀合物组合物和使用方法
|
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
|
WO2021037205A1
(zh)
|
2019-08-29 |
2021-03-04 |
苏州瑞博生物技术股份有限公司 |
化合物和药物缀合物及其制备方法和用途
|
|
JP7805286B2
(ja)
|
2019-09-03 |
2026-01-23 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
|
|
CA3152529A1
(en)
|
2019-09-03 |
2021-03-11 |
Arcturus Therapeutics, Inc. |
Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
WO2021072330A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
|
|
CN114728017B
(zh)
|
2019-10-14 |
2025-10-28 |
阿斯利康(瑞典)有限公司 |
Pnpla3表达的调节剂
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
US12491255B2
(en)
|
2019-10-14 |
2025-12-09 |
Aro Biotherapeutics Company |
EPCAM binding fibronectin type III domains
|
|
EP4045061A4
(en)
|
2019-10-14 |
2024-04-17 |
ARO Biotherapeutics Company |
CD71-BINDING FIBRONECTIN TYPE III DOMAINS
|
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CA3160329A1
(en)
*
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
WO2021096763A1
(en)
|
2019-11-13 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
US20210322339A1
(en)
|
2019-11-20 |
2021-10-21 |
Berg Llc |
Combination therapy of coenzyme q10 and radiation for treatment of glioma
|
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
WO2021119034A1
(en)
|
2019-12-09 |
2021-06-17 |
Amgen Inc. |
RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
|
|
JP2023514000A
(ja)
|
2019-12-09 |
2023-04-05 |
エンピリコ インク． |
アンジオポエチン様４（ａｎｇｐｔｌ４）関連疾患の処置のためのオリゴヌクレオチド
|
|
TWI897902B
(zh)
|
2019-12-13 |
2025-09-21 |
美商阿尼拉製藥公司 |
人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
|
|
EP4076434A1
(en)
|
2019-12-17 |
2022-10-26 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
CN111041025B
(zh)
|
2019-12-17 |
2021-06-18 |
深圳市瑞吉生物科技有限公司 |
基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
|
|
JP7681525B2
(ja)
|
2020-01-30 |
2025-05-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
核酸複合体及びそれを含む医薬組成物
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
|
KR20220143106A
(ko)
|
2020-02-18 |
2022-10-24 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
|
|
IL295605A
(en)
|
2020-02-28 |
2022-10-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
|
WO2021178725A1
(en)
|
2020-03-04 |
2021-09-10 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
KR20220152270A
(ko)
|
2020-03-06 |
2022-11-15 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
|
|
IL296109A
(en)
|
2020-03-06 |
2022-11-01 |
Alnylam Pharmaceuticals Inc |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
JP2023519215A
(ja)
|
2020-03-23 |
2023-05-10 |
アムジエン・インコーポレーテツド |
化学修飾核酸に対するモノクローナル抗体及びその使用
|
|
US20230134550A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
CA3172572A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
コロナウイルスｉＲＮＡ組成物およびその使用方法
|
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
EP4127134A4
(en)
|
2020-04-01 |
2024-07-31 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF
|
|
EP4133078A1
(en)
|
2020-04-06 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
KR20230008078A
(ko)
|
2020-04-07 |
2023-01-13 |
알닐람 파마슈티칼스 인코포레이티드 |
Scn9a 발현을 사일런싱하기 위한 조성물 및 방법
|
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
EP4132478A1
(en)
|
2020-04-09 |
2023-02-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
JP2023522961A
(ja)
|
2020-04-21 |
2023-06-01 |
フラッグシップ パイオニアリング， インコーポレイテッド |
二機能性分子およびその使用方法
|
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
|
US20240270780A1
(en)
*
|
2020-04-29 |
2024-08-15 |
Tai Bi Di Pharmaceutical Technology (Shijiazhuang) Co. Ltd |
Proteolysis targeting compound with tissue targeting capability and use thereof
|
|
WO2021222549A1
(en)
|
2020-04-30 |
2021-11-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
BR112022021333A2
(pt)
|
2020-05-01 |
2022-12-13 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular atxn1
|
|
IL298063A
(en)
|
2020-05-11 |
2023-01-01 |
Stoke Therapeutics Inc |
opa1 antisense oligomers for the treatment of conditions and diseases
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
CN113683651A
(zh)
*
|
2020-05-19 |
2021-11-23 |
上海京新生物医药有限公司 |
一种GalNAc中间体的制备方法
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
WO2021242883A1
(en)
|
2020-05-26 |
2021-12-02 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
IL298697A
(en)
|
2020-06-01 |
2023-02-01 |
Amgen Inc |
Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
AU2021292296A1
(en)
|
2020-06-18 |
2023-01-19 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
|
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
|
CN116096906A
(zh)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
|
|
CN111744019B
(zh)
*
|
2020-07-01 |
2023-08-04 |
深圳瑞吉生物科技有限公司 |
基于甘露糖的mRNA靶向递送系统及其应用
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
US20240018524A1
(en)
|
2020-07-10 |
2024-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating epilepsy
|
|
EP4182297B1
(en)
|
2020-07-16 |
2025-09-03 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
MX2023001222A
(es)
|
2020-07-28 |
2023-04-26 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de app.
|
|
MX2023001486A
(es)
|
2020-08-07 |
2023-03-27 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular scn2a.
|
|
MX2023001786A
(es)
|
2020-08-13 |
2023-03-10 |
Amgen Inc |
Construcciones de iarn y metodos para inhibir la expresion de marc1.
|
|
US20230303618A1
(en)
*
|
2020-08-21 |
2023-09-28 |
Reyoung Corporation |
Triptolide conjugates and uses thereof
|
|
UY39420A
(es)
*
|
2020-09-11 |
2022-03-31 |
Arrowhead Pharmaceuticals Inc |
Conjugados lipídicos para el transporte de agentes terapéuticos
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
WO2022079221A1
(en)
|
2020-10-16 |
2022-04-21 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
|
US20230383294A1
(en)
|
2020-10-16 |
2023-11-30 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl3
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
WO2022098841A1
(en)
|
2020-11-05 |
2022-05-12 |
Amgen Inc. |
METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
|
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
|
EP4488371A3
(en)
|
2020-11-18 |
2025-04-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
AU2021393417A1
(en)
|
2020-12-01 |
2023-06-29 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
IL303800A
(en)
|
2020-12-18 |
2023-08-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating factor xii
|
|
US20240058279A1
(en)
|
2020-12-21 |
2024-02-22 |
Flagship Pioneering Innovations V, Inc. |
Use of cell turnover factors for increasing tissue regeneration
|
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CN116669746B
(zh)
|
2020-12-29 |
2025-09-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2022172083A2
(en)
*
|
2021-01-21 |
2022-08-18 |
Sirnaomics, Inc. |
Targeted nucleic acid therapy for hepatitis b
|
|
AU2022213743A1
(en)
*
|
2021-01-28 |
2023-06-15 |
Nanjing Chempion Biotechnology Co., Ltd. |
Conjugate and use thereof
|
|
EP4175965B1
(en)
*
|
2021-01-30 |
2024-03-13 |
E-Therapeutics plc |
Conjugated oligonucleotide compounds, methods of making and uses thereof
|
|
JP2024504504A
(ja)
*
|
2021-01-30 |
2024-01-31 |
イー セラピューティクス パブリック リミテッド カンパニー |
コンジュゲートオリゴヌクレオチド化合物、その作製方法及び使用
|
|
TW202305131A
(zh)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
用於治療或預防超氧歧化酶１－（ＳＯＤ１－）相關的神經退化疾病的超氧歧化酶１（ＳＯＤ１）ｉＲＮＡ組成物及其使用方法
|
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
|
|
EP4298218A1
(en)
|
2021-02-26 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
IL305442A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
DK4161942T3
(da)
|
2021-03-19 |
2023-10-23 |
Bachem Holding Ag |
Forbedret oligonukleotidsyntese der undertrykker depurinering
|
|
EP4316495A4
(en)
*
|
2021-03-25 |
2025-12-31 |
Aptacure Therapeutics Ltd |
CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE
|
|
AU2022246144A1
(en)
|
2021-03-26 |
2023-09-21 |
Mina Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
EP4314296A2
(en)
|
2021-03-29 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
US20240402177A1
(en)
|
2021-04-06 |
2024-12-05 |
Bpgbio, Inc. |
Protein markers for estrogen receptor (er)-positive luminal a (la)-like and luminal b1 (lb1)-like breast cancer
|
|
US20240230651A1
(en)
|
2021-04-06 |
2024-07-11 |
Bpgbio, Inc. |
Protein markers for the prognosis of breast cancer progression
|
|
IL307531A
(en)
|
2021-04-06 |
2023-12-01 |
Bpgbio Inc |
Protein markers for estrogen receptor (ER)-like and estrogen receptor (ER)-negative breast cancer
|
|
CN115197078B
(zh)
*
|
2021-04-08 |
2024-06-04 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
US20240197633A1
(en)
*
|
2021-04-08 |
2024-06-20 |
Xiamen Sinopeg Biotech Co., Ltd. |
Pegylated lipid, liposome modified by the lipid, pharmaceutical composition containing the liposome, formulation and application thereof
|
|
WO2022214692A1
(en)
|
2021-04-09 |
2022-10-13 |
Bachem Holding Ag |
Pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates
|
|
CA3215367A1
(en)
|
2021-04-14 |
2022-10-20 |
Swapnil Kulkarni |
Fn3 domain-sirna conjugates and uses thereof
|
|
EP4323409A4
(en)
|
2021-04-14 |
2025-04-16 |
ARO Biotherapeutics Company |
CD71-BINDING FIBRONECTIN TYPE III DOMAINS
|
|
CA3217717A1
(en)
|
2021-04-23 |
2022-10-27 |
Ganna Bio, Inc. |
Glycan modified nucleic acids, methods of preparation, and therapeutic uses
|
|
CA3216106A1
(en)
|
2021-04-26 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
|
EP4329734A4
(en)
|
2021-04-26 |
2025-04-02 |
Celanese EVA Performance Polymers LLC |
Implantable device for the delayed release of a macromolecular drug compound
|
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスｄｎａベクター及びその使用
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
EP4347822A2
(en)
|
2021-06-04 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
BR112023026050A2
(pt)
|
2021-06-18 |
2024-03-05 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir expressão de ifnar1
|
|
AU2022298603A1
(en)
|
2021-06-21 |
2024-02-01 |
Shanghai Junshi Biosciences Co., Ltd. |
Sirna inhibiting angptl3 gene expression, and use thereof
|
|
CN115572241B
(zh)
*
|
2021-06-21 |
2024-08-30 |
润佳（苏州）医药科技有限公司 |
双价化合物、偶联物及其用途
|
|
MX2023015523A
(es)
|
2021-06-23 |
2024-03-11 |
Univ Massachusetts |
Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos.
|
|
CA3224374A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
EP4363580A1
(en)
|
2021-06-30 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
JPWO2023282345A1
(OSRAM)
|
2021-07-08 |
2023-01-12 |
|
|
|
TW202317147A
(zh)
|
2021-07-08 |
2023-05-01 |
日商日本新藥股份有限公司 |
析出抑制劑
|
|
US20240285547A1
(en)
|
2021-07-08 |
2024-08-29 |
Nippon Shinyaku Co., Ltd. |
Nephrotoxicity reducing agent
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
US20240309378A1
(en)
|
2021-07-16 |
2024-09-19 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate containing double-stranded oligonucleotide, and preparation methods and uses
|
|
CN120989078A
(zh)
|
2021-07-16 |
2025-11-21 |
瑞博泰克(山东)生物医药科技有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
|
MX2024000981A
(es)
|
2021-07-21 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso.
|
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
|
|
CN115920065A
(zh)
*
|
2021-08-02 |
2023-04-07 |
南方科技大学 |
一种可靶向去唾液酸糖蛋白受体的配体及其缀合物与用途
|
|
EP4380576A2
(en)
*
|
2021-08-03 |
2024-06-12 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白（TTR）iRNA组合物和其使用方法
|
|
JP2024528270A
(ja)
*
|
2021-08-04 |
2024-07-26 |
ヘパジーン セラピューティクス（エイチケー）リミティド |
治療活性剤の送達のためのリガンド共役体
|
|
PE20241132A1
(es)
|
2021-08-04 |
2024-05-24 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
|
|
CA3227661A1
(en)
|
2021-08-05 |
2023-02-09 |
Weimin Wang |
1'-alkyl modified ribose derivatives and methods of use
|
|
CN117858883A
(zh)
|
2021-08-09 |
2024-04-09 |
莱尔纳生物制药私人有限公司 |
GalNAc单体和GalNAc寡核苷酸缀合物
|
|
JP2024534766A
(ja)
|
2021-08-13 |
2024-09-26 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
|
|
EP4395790A2
(en)
|
2021-08-31 |
2024-07-10 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
CA3232387A1
(en)
*
|
2021-09-13 |
2023-03-16 |
Ganna Bio, Inc. |
Glycan conjugate compositions and methods
|
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
US20230241224A1
(en)
|
2021-09-22 |
2023-08-03 |
Sanegene Bio Usa Inc. |
2'-alkyl or 3'- alkyl modified ribose derivatives and methods of use
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
WO2023056440A1
(en)
|
2021-10-01 |
2023-04-06 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
WO2023059695A1
(en)
|
2021-10-05 |
2023-04-13 |
Sanegene Bio Usa Inc. |
Polyhydroxylated cyclopentane derivatives and methods of use
|
|
WO2023059629A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
|
|
EP4416287A1
(en)
|
2021-10-14 |
2024-08-21 |
Hemoshear Therapeutics, Inc. |
Compositions and methods of treating diseases associated with bile acid transporter
|
|
KR20240101590A9
(ko)
|
2021-10-15 |
2025-12-10 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달 irna 조성물 및 이를 이용하는 방법
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
JP2024539097A
(ja)
|
2021-10-22 |
2024-10-28 |
アムジェン インコーポレイテッド |
Ｇｐａｍ発現を阻害するためのｒｎａｉコンストラクト及びその使用方法
|
|
EP4423273A1
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20250019702A1
(en)
|
2021-11-10 |
2025-01-16 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
CA3237770A1
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4469575A2
(en)
|
2022-01-24 |
2024-12-04 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
CN117756866A
(zh)
|
2022-01-30 |
2024-03-26 |
大睿生物医药科技(上海)有限公司 |
含有n-乙酰半乳糖胺的靶向配体
|
|
CA3252536A1
(en)
|
2022-02-22 |
2023-08-31 |
Sanegene Bio Usa Inc. |
CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES MODIFIED AT THE 5' POSITION AND METHODS OF USE
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
TW202346589A
(zh)
|
2022-03-10 |
2023-12-01 |
日商日本新藥股份有限公司 |
抗病毒反義寡聚物
|
|
CA3245737A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
PRIME-BOOST HETEROLOGICAL VACCINE COMPOSITIONS AND METHODS OF USE
|
|
TW202345867A
(zh)
|
2022-03-16 |
2023-12-01 |
日商第一三共股份有限公司 |
抑制運鐵蛋白受體2表現的siRNA
|
|
WO2023176863A1
(ja)
|
2022-03-16 |
2023-09-21 |
第一三共株式会社 |
ＲＮＡｉ活性を有する化学修飾オリゴヌクレオチド
|
|
TW202400787A
(zh)
|
2022-03-16 |
2024-01-01 |
美商安彼瑞可股份有限公司 |
改良siRNA生物可利用性之GalNAc組合物
|
|
US12258563B2
(en)
|
2022-03-28 |
2025-03-25 |
Empirico Inc. |
Modified oligonucleotides
|
|
CN119213006A
(zh)
*
|
2022-04-26 |
2024-12-27 |
康涅狄格大学 |
用于增强肝脏和肾脏特异性靶向的遗传序列-糖缀合物
|
|
WO2023220561A1
(en)
|
2022-05-09 |
2023-11-16 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
|
|
JP2025516680A
(ja)
|
2022-05-13 |
2025-05-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
一本鎖ループオリゴヌクレオチド
|
|
US20230372508A1
(en)
|
2022-05-19 |
2023-11-23 |
Olix Us, Inc. |
Linkers coupling functional ligands to macromolecules
|
|
JP2025522453A
(ja)
|
2022-06-14 |
2025-07-15 |
大睿生物 |
環状ホスホン酸エステル修飾ヌクレオチド
|
|
JP2025520520A
(ja)
*
|
2022-06-14 |
2025-07-03 |
大睿生物 |
ＰＣＳＫ９遺伝子活性を調節するｓｉＲＮＡ分子
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
WO2024001170A1
(en)
*
|
2022-06-27 |
2024-01-04 |
Ractigen Therapeutics |
Small activating nucleic acid molecule and use thereof in treatment of hereditary angioedema
|
|
CN119421952A
(zh)
|
2022-06-27 |
2025-02-11 |
大睿生物医药科技(上海)有限公司 |
抑制载脂蛋白C3表达的siRNA
|
|
AU2023307152A1
(en)
|
2022-07-11 |
2025-01-09 |
Sanegene Bio Usa Inc. |
Optimized 2'- modified ribose derivatives and methods of use
|
|
CN119677851A
(zh)
|
2022-07-25 |
2025-03-21 |
安进公司 |
用于抑制FAM13A表达的RNAi构建体和方法
|
|
US20240052348A1
(en)
|
2022-08-05 |
2024-02-15 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
JP2025530741A
(ja)
|
2022-08-29 |
2025-09-17 |
ユニヴァーシティ オヴ ロチェスター |
アンチセンスオリゴヌクレオチドベースの抗線維化治療剤
|
|
JP2025532593A
(ja)
|
2022-09-15 |
2025-10-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
１７ｂ－ヒドロキシステロイドデヒドロゲナーゼ１３型（ｈｓｄ１７ｂ１３）ｉｒｎａ組成物およびその使用方法
|
|
WO2024061842A1
(en)
|
2022-09-19 |
2024-03-28 |
Bachem Holding Ag |
Improved oligonucleotide synthesis
|
|
WO2024064858A2
(en)
|
2022-09-23 |
2024-03-28 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing mecp2 expression
|
|
JP2025533501A
(ja)
|
2022-09-28 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
ポンペ病マウスモデルの生成、特徴決定および使用方法
|
|
JP2025532985A
(ja)
|
2022-09-30 |
2025-10-03 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
修飾二本鎖ｒｎａ剤
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
AU2023358547A1
(en)
|
2022-10-14 |
2025-04-24 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting c3 and uses thereof
|
|
WO2024083746A1
(en)
|
2022-10-17 |
2024-04-25 |
Bachem Holding Ag |
Method and composition for oligonucleotide synthesis
|
|
CN120225676A
(zh)
|
2022-12-02 |
2025-06-27 |
上海舶望制药有限公司 |
双环脱碱基核酸类似物以及由它们制备的寡聚化合物
|
|
AU2023387789A1
(en)
*
|
2022-12-08 |
2025-06-26 |
Nanovation Therapeutics Inc. |
Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid
|
|
US20240293555A1
(en)
*
|
2022-12-12 |
2024-09-05 |
University Of Massachusetts |
Carbohydrate conjugates for the delivery of therapeutic oligonucleotides
|
|
EP4634385A2
(en)
|
2022-12-16 |
2025-10-22 |
Amgen Inc. |
Rnai constructs for inhibiting ttr expression and methods of use thereof
|
|
AU2023408479A1
(en)
|
2022-12-19 |
2025-05-01 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar)
|
|
CN120569477A
(zh)
|
2022-12-19 |
2025-08-29 |
美国圣因生物股份有限公司 |
靶向cfb的小干扰rna及其用途
|
|
ES3030929T3
(en)
|
2022-12-19 |
2025-07-02 |
Arnatar Therapeutics Inc |
Arnatar compounds and methods for enhanced cellular uptake
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240254485A1
(en)
|
2023-01-13 |
2024-08-01 |
Hemoshear Therapeutics, Inc. |
Sirnas targeting slc10a1 transcripts, compositions and uses thereof
|
|
CN120813691A
(zh)
|
2023-02-09 |
2025-10-17 |
阿尔尼拉姆医药品有限公司 |
Reversir分子及其使用方法
|
|
WO2024175111A2
(en)
|
2023-02-24 |
2024-08-29 |
Suzhou Sanegene Bio Inc. |
Small interfering rna targeting hbv and uses thereof
|
|
WO2024186673A2
(en)
|
2023-03-03 |
2024-09-12 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting apoc3 and uses thereof
|
|
EP4678746A1
(en)
|
2023-03-10 |
2026-01-14 |
Suzhou Ribo Life Science Co., Ltd. |
Pharmaceutical composition and use thereof
|
|
WO2024206230A1
(en)
*
|
2023-03-24 |
2024-10-03 |
Trustees Of Tufts College |
Tissue targeting lipids and lipid nanoparticles
|
|
CN121399143A
(zh)
*
|
2023-04-19 |
2026-01-23 |
普拉姆医药公司 |
脂质纳米颗粒(lnp)递送系统和制剂
|
|
WO2024220930A2
(en)
|
2023-04-20 |
2024-10-24 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
US20250018045A1
(en)
|
2023-05-03 |
2025-01-16 |
Sanegene Bio Usa Inc. |
Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery
|
|
AU2024269205A1
(en)
|
2023-05-11 |
2025-12-11 |
Keymed Biosciences (Us) Inc. |
Dsrna molecules for regulating masp2 gene activity
|
|
CN118930593A
(zh)
|
2023-05-11 |
2024-11-12 |
广东东阳光药业股份有限公司 |
一种新型的靶向化合物和核酸缀合物，及其用途
|
|
WO2024238385A2
(en)
|
2023-05-12 |
2024-11-21 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
CN118993970B
(zh)
*
|
2023-05-17 |
2025-12-23 |
苏州富士莱医药股份有限公司 |
一种l96侧链化合物的制备方法
|
|
WO2024240212A1
(zh)
|
2023-05-24 |
2024-11-28 |
云合智药（苏州）生物科技有限公司 |
用于抑制angptl3表达的rnai剂及其应用
|
|
CN121335980A
(zh)
|
2023-05-26 |
2026-01-13 |
阿达尔克斯制药有限公司 |
Sod1调节组合物及其使用方法
|
|
WO2024249889A1
(en)
*
|
2023-05-31 |
2024-12-05 |
University Of Connecticut |
Genetic sequence/small molecule-carbohydrate conjugates for enhanced lung-specific targeting
|
|
WO2024259134A1
(en)
|
2023-06-13 |
2024-12-19 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar) for angiotensinogen
|
|
AU2024313301A1
(en)
|
2023-06-20 |
2025-12-11 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
US20250027089A1
(en)
|
2023-06-21 |
2025-01-23 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof
|
|
US12508320B2
(en)
|
2023-06-29 |
2025-12-30 |
SeeCure Taiwan Co., Ltd. |
Drug conjugate, pharmaceutical composition and method of treating hepatitis
|
|
WO2025002208A1
(zh)
*
|
2023-06-30 |
2025-01-02 |
苏州时安生物技术有限公司 |
一种核酸缀合物、制备方法及用途
|
|
WO2025007961A1
(zh)
|
2023-07-06 |
2025-01-09 |
大睿生物 |
调控AGT表达的dsRNA分子
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
GB202311334D0
(en)
|
2023-07-24 |
2023-09-06 |
Astrazeneca Ab |
Multivalent cargo-carrying complexes and uses thereof
|
|
GB202311324D0
(en)
|
2023-07-24 |
2023-09-06 |
Astrazeneca Ab |
Multivalent cargo-carrying complexes and uses thereof
|
|
WO2025024523A1
(en)
|
2023-07-24 |
2025-01-30 |
Sanegene Bio Usa Inc. |
Lipid-based enhancement agent for rna delivery and therapy
|
|
US20250051771A1
(en)
|
2023-07-24 |
2025-02-13 |
Astrazeneca Ab |
Multivalent cargo-carrying complexes and uses thereof
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
GB202314724D0
(en)
|
2023-09-26 |
2023-11-08 |
Astrazeneca Ab |
compounds and methods for reducing psd3 expression
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
WO2025080572A1
(en)
|
2023-10-10 |
2025-04-17 |
Avanti Polar Lipids, Llc |
Liver asialoglycoprotein receptor targeted lipid and uses thereof
|
|
WO2025082632A1
(en)
|
2023-10-16 |
2025-04-24 |
Bachem Holding Ag |
Method and composition for oligonucleotide synthesis
|
|
WO2025085732A1
(en)
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Humanized dnm2 mouse model generation, characterization and methods of use
|
|
WO2025090796A1
(en)
*
|
2023-10-24 |
2025-05-01 |
University Of Connecticut |
Carbohydrate ligands and uses thereof
|
|
AU2024369609A1
(en)
|
2023-10-31 |
2025-12-11 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
WO2025097126A1
(en)
*
|
2023-11-03 |
2025-05-08 |
Vionelix Pharmaceuticals, Inc. |
Mutation-resistant anti-viral compositions
|
|
WO2025077949A1
(zh)
*
|
2023-11-06 |
2025-04-17 |
杭州天龙药业有限公司 |
提升双链寡核苷酸靶基因抑制效果的修饰模板及其组合与应用
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
WO2025155911A1
(en)
|
2024-01-18 |
2025-07-24 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of hurler syndrome
|
|
WO2025157273A1
(en)
*
|
2024-01-25 |
2025-07-31 |
Shanghai Rona Therapeutics Co., Ltd. |
Two or more nucleic acid molecules connected by a linker
|
|
WO2025165891A1
(en)
|
2024-01-29 |
2025-08-07 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
EP4665854A1
(en)
|
2024-01-29 |
2025-12-24 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
WO2025193807A1
(en)
|
2024-03-12 |
2025-09-18 |
Sarepta Therapeutics, Inc. |
Humanized umod mouse model generation, characterization and methods of use
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224036A1
(en)
|
2024-04-22 |
2025-10-30 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
WO2025228441A2
(en)
|
2024-04-30 |
2025-11-06 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting inhbe and uses thereof
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026006275A2
(en)
|
2024-06-26 |
2026-01-02 |
Amgen Inc. |
Rnai constructs and methods for inhibiting expression of inhbe
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
US20260015617A1
(en)
|
2024-07-12 |
2026-01-15 |
Novartis Ag |
DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE
|
|
WO2026017140A2
(en)
|
2024-07-18 |
2026-01-22 |
Sanegene Bio Usa Inc. |
Small interfering rna targeting fxi and uses thereof
|